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Chronic myeloid leukemia is a clonal hematopoietic stem cell disorder in which leukemic cells display a distinctive shortened chromosome, the Philadelphia (ph) chromosome generated from a reciprocal t(9:22) translocation. This translocation results in the head-to-tail fusion of the breakpoint cluster region (BCR) gene on chromosome 22 with the ABL proto-oncogene on chromosome 9. The encoded chimeric Bcr-Abl oncoprotein exhibits constitutive tyrosine kinase activity leading to its autophosphorylation, to activation of multiple signaling molecules, including p21Ras, signal transducer and activator of transcription 5 (STAT5),  phosphoinositide 3-kinase (PI3-kinase) and integrin-linked pathways.  As a consequence, Bcr-Abl leads to increased proliferation, inhibition of apoptosis and altered adhesion of leukemic blasts to bone marrow (BM) microenvironment. The understanding the process of leukemogenesis driven by this oncogene is still an important research objective. At this regard a field of investigation is represented by the study of bone marrow (BM) microenvironment as active participant in resistance to therapies. This microenvironment is characterized by different populations of accessory stromal and T cells along with other factors including extracellular matrix and vessels. A large number of evidences indicate  that BM is the source of signals, both soluble and insoluble, which modulate the growth, long-term survival, disease progression  and importantly the drug-response of various hematologic malignancies, including precursor B-lineage acute lymphoblastic leukemia and CML. Additionally, other studies showed that increased bone marrow vascularity (angiogenesis) is part of the pathophysiology of human CML. Patients with CML in blastic phase (CML-BP) have a marked increase in bone marrow microvessel density where it represents an independent, adverse prognostic feature. 
Microvesiscles released by malignant cancer cells constitute an important part of the tumor-microenvironment as they can transfer various messages to target cells and may be critical to disease progression. Among microvesiscles types, exosomes have attracted recently the attention of scientists for their possible role in cell-to-cell communication [\o "Johnstone, 2006 #42"]. Exosomes are small vesicles of 40-100 nm diameter that are initially formed within the endosomal compartment and are secreted when a multivesicular body (MVB) fuses with the plasma membrane [\o "Schorey, 2008 #15"]. These vesicles are released by many cell types including reticulocytes, T lymphocytes, mast cells and epithelial cells [3, \o "Admyre, 2007 #17"]. It is known that exosomes transport pro-apoptotic, regulatory proteases and angiogenic molecules [5, 6]. Although only few papers have indicated the production of exosomes in CML cells, namely K562 cells [\o "Savina, 2003 #64"] no data are available regarding the possible role of these vesiscles in CML biology.
Studies performed in our laboratory highlighted that also LAMA84 CML cells release exosomes and we evaluated the effects of these microvescicles on endothelial cells representing one of major cytotype of bone marrow microenvironment. Firstly, since exosomes functionality appears to be determined by its specific protein content, exosomes derived by LAMA84 cells were analysed by a MudPIT-based proteomics analysis, by using a high mass accuracy Orbitrap MS and rigorous identification criteria. The obtained data confirmed that the isolated vesicles were exosomes and also provided more and useful information regarding the comprehensive proteome profile of these microvesicles. Furthermore, functional experimental data showed that the addition of microvesiscles to endothelial cells (EC) stimulated an angiogenic phenotype. Motility assays demonstrated the ability of LAMA84 exosomes to increase the migrating activity of EC and this observation was also confirmed by wound healing assays. Moreover, we also highlighted, by Real Time PCR analyses, that EC stimulated by exosomes increased expression of adhesion molecules (ICAM-1, VCAM-1 and E-selectin) and production of the angiogenic IL-6 as well as other cytokines involved in paracrine cross-talk with leukemia cells. In order to better understand the functional meaning of the increased expression of adhesion molecules, we performed adhesion assays of CML cell on HUVEC monolayer. The results showed that the number of adhered CML cells increased in function of exosomes dose. On the other side, confocal microscopy experiments showed that exosomes treatment induced in EC cells the delocalization of VE-cadherin and β-catenin from plasma membrane to cytoplasm. Overall these observations may support the hypothesis that exosomes released by CML cells facilitate the in vivo intravasation of leukemic blasts and consequently their diffusion by bloodstream. Finally, the pro-angiogenetic role of LAMA84 exosomes was also confirmed by in vivo experiments on nude mice. Actually, we are deeply analysing the proteomic data in order to show up the presence in exosomes of proteins having specific roles in regulation of the biologic processes we observed. The comprehension of new cross-talk mechanisms and new molecular targets involved in leukemic cells diffusion may contribute to develop new therapeutic approach for the treatment of CML.

REFERENCES
1.	Johnstone R. Blood Cells Mol Dis, 2006. 36: p. 315-321.
2.	Schorey J. and Bhatnagar S.. Traffic, 2008. 9(6): p. 871-881.
3.	Al-Nedawi K. Et al. Arterioscler Thromb Vasc Biol, 2005. 25(8): p. 1744-1749.
4.	Admyre C. et al. J Immunol 2007. 179(3): p. 1969-1978.
5.	Ristorcelli E. et al. Int J Cancer, 2009. 125(5): p. 1016-1026.
6.	Taverna S. et al. FEBS J, 2008. 275(7): p. 1579-9152.
7. 	Savina A. et al. Journal of Biological Chemestry, 2003. 278(22): p. 20082-20090.

